Description

Global biotech/pharma executive with 30+ years of leadership in medical affairs, clinical development, and business development at Janssen, Novo Nordisk, Amgen, and Biogen. Combines medical expertise with strategic vision to build high-performing global R&D organizations. Proven record in biosimilars, regulatory approvals, and real-world evidence impacting 270,000+ patients. Recognized for advancing therapeutic outcomes in immunology, ophthalmology, and nephrology.

Built and successfully led end to end medical global teams

Launched more than 15 biologics

Languages

English
Native or bilingual
Arabic
Native or bilingual
French
Conversational
German
Basic

Workplace preferences

Can work on-site

Zug (up to 50km)

Biogen
Vice President, Global Head of Medical & Development
January 2020 - June 2025 (5 years and 5 months)
Baar, Switzerland
• • Established global R&D organization for biosimilars (90+ staff),
• • Led successful development & filings of 8 biologics (5 launched), in 4 therapeutic areas. (PTRS of 90%)
• • Led scientific engagements with FDA and EMA which resulted in early alignment of expedited and cost efficient development pathways
• • Codesigned and executed (4) phase I and (5) phase III studies with high scientific quality
• • Passed 25 internal and external audits with no critical findings
• • Established a stand alone PV global model that was later on adopted by the mother company
• • Secured partnerships (Samsung Bioepis, Biothera), driving 20% portfolio growth
Biogen
Vice President, Global Head of Medical & Development
BIOTECH
January 2020 - June 2025 (5 years and 5 months)
Baar, Switzerland
• Established global R&D organization for biosimilars (90+ staff), improving efficiency by 30%.
• Led
• Led development & filings of 8 biologics (5 launched), reaching 270,000 patients
• Secured partnerships (Samsung Bioepis, Biothera), driving 20% portfolio growth.
• Authored 300+ publications supporting real-world evidence for 110,000 patients.
Business development senior leadership Clinical development and RWE /IISs medical affairs planning scientific publications
Biogen
Global Head of Medical Affairs – Immunology/Biosimilars
January 2015 - January 2020 (5 years)
Baar, Switzerland
• • Built medical affairs team launching 5 biosimilars, delivering $300M first-year revenue.
• • Generated Real world evidence from 110,000 patients disseminated in 300+ abstracts/publications
• • Co/led revisions of HTAs and generation of value dossiers, partnership with key payers for advancing reimbursement criteria
• • Worked closely with key global clinical societies for advancing treatment guidelines to help advancing treatment outcomes based on newly generated evidence and cost effectiveness data
• • Implemented global risk management plans for 5 assets in close collaboration with FDA and EMA
• • Established global medical educational programs leveraging omnichannel enabling reach to 100,000 HCPs
• • Established well recognized patient support programs across Europe with more than 60,000 patients enrolled and collaborated with Key European patient advocacy groups
• • Established global medical information platforms and call centers dealing with up to 10000 inquiries annually